Antibody drug conjugates (ADCs) have emerged as one of the most rapidly evolving modalities in oncology drug development. With 14 FDA-approved ADCs currently on the market and more than 1,100 in active development, the field is advancing at a pace that demands scientific rigor and operational sophistication. Watch our webinar, as a panel of experts examines the critical scientific, regulatory, and operational factors that define successful ADC development, from first-in-human trials through registrational strategy.
In this webinar, you will:
- Gain insights into ADC science, including next-generation innovations in linker chemistry, payloads, and new formats that address tumor heterogeneity and resistance
- Learn practical approaches to dose selection in ADC trials, applying Project Optimus principles, pharmacokinetic modeling, and managing therapeutic windows
- Understand key regulatory and biomarker requirements, including companion diagnostics, target cutoffs, and accelerated approval considerations
- Review operational strategies for ADC trials, including toxicity monitoring, supply planning, and standardization of practices across global sites
